1,586
Views
3
CrossRef citations to date
0
Altmetric
Articles

Biliary complications and efficacy after ablation of peribiliary tumors using irreversible electroporation (IRE) or radiofrequency ablation (RFA)

ORCID Icon, , ORCID Icon, , , & show all
Pages 751-757 | Received 04 Dec 2021, Accepted 15 May 2022, Published online: 01 Jun 2022

References

  • Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):751–424.
  • Virani S, Bilheem S, Chansaard W, et al. National and subnational Population-Based incidence of cancer in Thailand: assessing cancers with the highest burdens. Cancers (Basel). 2017;9(12):108.
  • Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314.
  • Hu H, Chi JC, Liu R, et al. Microwave ablation for peribiliary hepatocellular carcinoma: propensity score analyses of long-term outcomes. Int J Hyperthermia. 2021;38(1):191–201.
  • McGhana JP, Dodd GD. 3rd. Radiofrequency ablation of the liver: current status. AJR Am J Roentgenol. 2001;176(1):3–16.
  • Teratani T, Yoshida H, Shiina S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology. 2006;43(5):1101–1108.
  • Kang TW, Lim HK, Lee MW, et al. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes. Radiology. 2014;270(3):888–899.
  • Kalra N, Gupta P, Gorsi U, et al. Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience. Cardiovasc Intervent Radiol. 2019;42(4):584–590.
  • Fang C, Kibriya N, Heaton ND, et al. Safety and efficacy of irreversible electroporation treatment in hepatobiliary and pancreatic tumours: a single-Centre experience. Clin Radiol. 2021;76(8):599–606.
  • Hui TC, Kwan J, Pua U. Advanced techniques in the percutaneous ablation of liver tumours. Diagnostics (Basel). 2021;11(4):585.
  • Faroja M, Ahmed M, Appelbaum L, et al. Irreversible electroporation ablation: is all the damage nonthermal? Radiology. 2013;266(2):462–470.
  • Distelmaier M, Barabasch A, Heil P, et al. Midterm safety and efficacy of irreversible electroporation of malignant liver tumors located close to major portal or hepatic veins. Radiology. 2017;285(3):1023–1031.
  • Ruarus AH, Barabasch A, Catalano O, et al. Irreversible electroporation for hepatic tumors: protocol standardization using the modified delphi technique. J Vasc Interv Radiol. 2020;31(11):1765–1771.e15.
  • Sacks D, McClenny TE, Cardella JF, et al. Society of interventional radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14(9 Pt 2):S199–S202.
  • Silk MT, Wimmer T, Lee KS, et al. Percutaneous ablation of peribiliary tumors with irreversible electroporation. J Vasc Intervent Radiol. 2014;25(1):112–118.
  • Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241–260.
  • Lu DS, Yu NC, Raman SS, et al. Radiofrequency ablation of hepatocellular carcinoma: treatment success as defined by histologic examination of the explanted liver. Radiology. 2005;234(3):954–960.
  • Charpentier KP, Wolf F, Noble L, et al. Irreversible electroporation of the liver and liver hilum in swine. HPB (Oxford). 2011;13(3):168–173.
  • Ridouani F, Ghosn M, Cornelis F, et al. Ablation zone involution of liver tumors is faster in patients treated with irreversible electroporation than microwave ablation. Medicina (Kaunas). 2021;57(9):877.
  • Lee KW, Lee JM, Choi HS, et al. Novel ablation therapy using endoscopic irreversible electroporation in the bile duct: a pilot animal study. Clin Endosc. 2021;54(3):413–419.
  • Li Q, Ren F, Zhang Y, et al. Acute and subacute effects of irreversible electroporation on normal common bile ducts in a rabbit model. J Hepatobiliary Pancreat Sci. 2020;27(10):776–784.
  • Ueshima E, Schattner M, Mendelsohn R, et al. Transmural ablation of the normal porcine common bile duct with catheter-directed irreversible electroporation is feasible and does not affect duct patency. Gastrointest Endosc. 2018;87(1):300.e1–e6.
  • van Tilborg AA, Scheffer HJ, de Jong MC, et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and Lesion-Based analysis of two historical cohorts. Cardiovasc Intervent Radiol. 2016;39(10):1438–1446.
  • Thamtorawat S, Limsuwarn P, Tongdee T, et al. Incidence of complication and tumor recurrence after radiofrequency ablation in high-risk location of hepatocellular carcinoma patients. J Med Assoc Thai. 2014;97(1):95–100.
  • Freeman E, Cheung W, Ferdousi S, et al. Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single Centre propensity-matched comparison. Scand J Gastroenterol. 2021;56(8):942–947.